PCRX News and Press, Pacira BioSciences Inc. From 04/05/22

TAMPA, Fla., April 05, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 21 st Annual Needham Virtual Healthcare Conference at 8:45 AM ET on Tuesday, April 12, 2022. Live audio of the even...

Heron has lost 60% of its value in less than a year, despite the company making some progress. Zynrelef's launch is slow but showing signs of improvement with some important inflection points. CINV franchise has also disappointed and HTX-019 in PONV is now the only likely growth d...

Pacira BioSciences (NASDAQ:PCRX) reported February preliminary net product sales for EXPAREL (bupivacaine liposome injectable suspension) of $41.7M. EXPAREL average daily sales for the month of February 2022 were 117% of February 2021. Net product sales for iovera of $0.9M for the month....

TAMPA, Fla., March 15, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales for EXPAREL ® (bupivacaine liposome...

TAMPA, Fla., March 09, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays Global Healthcare Conference at 10:15 AM ET on Wednesday, March 16, 2022 in Miami. Live audio of the event can...

John Paulson’s 13F portfolio value decreased from $3.51B to $3.24B this quarter. Paulson & Company increased Pacira Biosciences and SSR mining while reducing Brightsphere Investment Group and Thryv Holdings. The top three positions are at 49% of the portfolio. For...

Pacira BioSciences, Inc. (PCRX) Q4 2021 Earnings Conference Call February 24, 2022 8:30 a.m. ET Company Participants Susan Mesco - Investor Relations Dave Stack - Chairman and Chief Executive Officer Charlie Reinhart - Chief Financial Officer Roy Winston - Chief Medical Officer Conference Cal...

The following slide deck was published by Pacira BioSciences, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Pacira BioSciences, Inc. 2021 Q4 - Results - Earnings Call Presentation

Pacira BioSciences press release (NASDAQ:PCRX): Q4 Non-GAAP EPS of $0.97 beats by $0.14. Revenue of $159.19M (+21.5% Y/Y) beats by $1.77M. “The acquisition of Flexion Therapeutics combined with record EXPAREL sales resulted in a pivotal year for Pacira, allowing us to enter 2022 in the...

— Anesthesia-driven regional approaches drive record EXPAREL sales of $507 million in 2021 — — Full-year GAAP net income of $42 million and adjusted EBITDA of $204 million — — More than 10 million patients have received EXPAREL since launch &...